Homologous and Heterologous Covid-19 Booster Vaccinations

BACKGROUND: Although the three vaccines against coronavirus disease 2019 (Covid-19) that have received emergency use authorization in the United States are highly effective, breakthrough infections are occurring. Data are needed on the serial use of homologous boosters (same as the primary vaccine)...

Descripción completa

Detalles Bibliográficos
Autores principales: Atmar, Robert L., Lyke, Kirsten E., Deming, Meagan E., Jackson, Lisa A., Branche, Angela R., El Sahly, Hana M., Rostad, Christina A., Martin, Judith M., Johnston, Christine, Rupp, Richard E., Mulligan, Mark J., Brady, Rebecca C., Frenck, Robert W., Bäcker, Martín, Kottkamp, Angelica C., Babu, Tara M., Rajakumar, Kumaravel, Edupuganti, Srilatha, Dobrzynski, David, Coler, Rhea N., Posavad, Christine M., Archer, Janet I., Crandon, Sonja, Nayak, Seema U., Szydlo, Daniel, Zemanek, Jillian A., Dominguez Islas, Clara P., Brown, Elizabeth R., Suthar, Mehul S., McElrath, M. Juliana, McDermott, Adrian B., O’Connell, Sarah E., Montefiori, David C., Eaton, Amanda, Neuzil, Kathleen M., Stephens, David S., Roberts, Paul C., Beigel, John H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Massachusetts Medical Society 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820244/
https://www.ncbi.nlm.nih.gov/pubmed/35081293
http://dx.doi.org/10.1056/NEJMoa2116414

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820244/
https://www.ncbi.nlm.nih.gov/pubmed/35081293
http://dx.doi.org/10.1056/NEJMoa2116414

Ejemplares similares